Aurobindo Pharma subsidiary gets USFDA nod for vasoconstrictor drug

16 Aug 2022 , 10:16 AM

Vasopressin injection USP is indicated for the treatment of Cardiovascular agent: vasoconstrictor. Indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. Vasopressin injection USP, would be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vasostrict Injection, 20 units/mL of Par Sterile Products, LLC (Par). The product is being launched immediately. According to IQVIA, The approved product has an estimated market size of around $606 million for the twelve months ending June 2022. This is the 146th ANDA (including 10 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) facilities, manufacturing both oral and sterile specialty products, the company stated. Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The pharmaceutical company reported 32.4% fall in consolidated net profit to Rs 520.5 crore in Q1 FY23 from Rs 770 crore in Q1 FY22. Revenue from operations increased by 9.4% YoY to Rs 6,235.9 crore during the period under review. Shares Aurobindo Pharma were up 0.19% to Rs 594.40 on the BSE. Powered by Capital Market – Live News